$KTTA SEC Filings

Filed On	Filing
16 Sep 2026	25-NSE
16 Sep 2026	8-K: Other Events The warrants of Pasithea Therapeutics Corp. (the “Company”) to purchase shares of the Company's common stock, which trade on The Nasdaq Capital Market (“Nasdaq”) under the symbol “KTTAW” (the “Warrants”), will expire on September 17, 202...
09 Sep 2026	8-K: Submission of Matters to a Vote of Security Holders On September 9, 2026, the Company held its Annual Meeting. The stockholders of the Company acted upon the following three proposals at the Annual Meeting: (1) the election of two Class III directors; (2) the ratification of the appointme...
21 Aug 2026	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
14 Aug 2026	SCHEDULE 13G/A
14 Aug 2026	QUARTERLY REPORT
07 Aug 2026	FORM ARS
07 Aug 2026	Proxy statement: annual meeting on September 9, 2026
31 Jul 2026	SCHEDULE 13G/A
29 Jul 2026	PRELIMINARY PROXY STATEMENT
01 Jul 2026	SCHEDULE 13G/A
23 Jun 2026	SCHEDULE 13G
22 Jun 2026	Form 4: Coastlands Capital Lp, 10% owner Bought 100,000 shares ($53K)
15 May 2026	SCHEDULE 13G/A
15 May 2026	QUARTERLY REPORT
05 May 2026	Form 4: Marques Tiago, Director Granted 1,756,069 Stock Option (right to buy)
05 May 2026	Form 4: Steinman Lawrence, Director Granted 152,783 Stock Option (right to buy)
05 May 2026	Form 4: Dumesnil Simon, Director Granted 152,783 Stock Option (right to buy)
05 May 2026	Form 4: Schneiderman Daniel H, Chief Financial Officer Granted 1,129,323 Stock Option (right to buy)
05 May 2026	Form 4: Krishnan Kartik, Chief Medical Officer Granted 1,129,323 Stock Option (right to buy)

Comments